Depletion of Intracellular Calcium Stores Activates Smooth Muscle Cell Calcium-independent Phospholipase A2
A NOVEL MECHANISM UNDERLYING ARACHIDONIC ACID MOBILIZATION*

(Received for publication, October 22, 1996, and in revised form, October 30, 1996)

Matthew J. Wolf Dagger , Jian Wang Dagger , John Turk § and Richard W. Gross Dagger

From the Dagger  Division of Bioorganic Chemistry and Molecular Pharmacology, Departments of Medicine, Chemistry, Molecular Biology and Pharmacology, Laboratory Medicine, and § Mass Spectrometry Resource, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Herein we present multiple lines of evidence which demonstrate that depletion of internal calcium stores is both necessary and sufficient for the activation of calcium-independent phospholipase A2 during arginine vasopressin (AVP)-mediated mobilization of arachidonic acid in A-10 smooth muscle cells. First, AVP-induced [3H]arachidonic acid release was independent of increases in cytosolic calcium yet was decreased by pharmacological inhibition of the release of calcium ion from internal stores. Second, thapsigargin induced the dramatic release of [3H]arachidonic acid from A-10 cells at a similar rate as the AVP-induced release of arachidonic acid, and the release of arachidonic acid by either AVP or thapsigargin was entirely inhibited by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL). Third, the magnitude of thapsigargin-induced [3H]arachidonic acid release was entirely independent of alterations in cytosolic calcium concentration. Fourth, A23187 resulted in the BEL-inhibitable release of [3H]arachidonic acid from A-10 cells even when ionophore-induced increases in cytosolic calcium were completely prevented by calcium chelators. Fifth, pretreatment of A-10 cells with a calmodulin antagonist (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, HCl) resulted in the time-dependent decrease of subsequent thapsigargin-induced [3H]arachidonic acid release. Collectively, these results identify a novel paradigm which links alterations in calcium homeostasis to the calmodulin-mediated regulation of calcium-independent phospholipase A2 through the depletion of internal calcium stores.


INTRODUCTION

Alterations in cellular calcium homeostasis are a widely employed and potent regulatory mechanism that modulates many functionally distinct physiologic processes (1-6). Historically, attention has focused on alterations in cytosolic free calcium as the primary mechanism through which calcium mediates its downstream effects on cellular biochemical events (7-9). However, recent studies have identified intracellular calcium store depletion as an important mechanism mediating calcium signaling in activated cells (10-12). For example, intracellular calcium store depletion regulates transplasmalemmal calcium flux (13, 14), hormone secretion (15, 16), and cellular proliferation (17-19). Although the importance of intracellular calcium store depletion is now well established, the precise biochemical mechanisms which link the depletion of intracellular calcium stores to cellular signaling processes remains enigmatic.

Eicosanoids are critical lipid second messengers in stimulated cells whose production has traditionally been envisaged to result from increases in cytosolic calcium leading to the activation of one or more calcium-dependent phospholipases A2 (e.g. cPLA2, sPLA2)1 (20, 21). Recently, we have demonstrated that the predominant phospholipase A2 activity in A-10 muscle cells is not activated by calcium ion (i.e. it is a member of the iPLA2 family) (22, 23) and that this iPLA2 is physically associated with, and functionally coupled to, the intracellular calcium signal transducer, calmodulin (24). In this paradigm, iPLA2 exists in a ternary complex with calcium and calmodulin in a catalytically inactive state. Pharmacologic removal of calmodulin from the phospholipase A2 ternary complex by W-7 in intact A-10 smooth muscle cells results in the activation of iPLA2 and the release of arachidonic acid (24). Accordingly, one mechanism potentially responsible for the release of arachidonic acid in activated cells is the depletion of calcium ion from specific subcellular loci and the resultant release of calmodulin-mediated inhibition of iPLA2.

A-10 smooth muscle cells contain arginine vasopressin (AVP) receptors whose occupancy results in the activation of PLC (25), the generation of IP3 (25, 26), and the subsequent release of calcium ion from internal stores (25-27). In previous studies, we utilized specific mechanism-based inhibition to demonstrate that AVP-induced release of arachidonic acid in A-10 smooth muscle cells occurs through the activation of iPLA2 (22). We now report that AVP-induced release of arachidonic acid catalyzed by iPLA2 is mediated by the depletion of internal calcium stores and that depletion of internal calcium stores, even in the absence of receptor occupancy or elevations of cytosolic free calcium, is sufficient for the activation of iPLA2.


EXPERIMENTAL PROCEDURES

Materials

A-10 cells derived from rat aortic smooth muscle (ATTC no. CRL 1476) were obtained from ATTC. (E)-6-(Bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL), thapsigargin, cyclopiazonic acid, 2,5-di-(t-butyl)-1,4-hydroquinone (BHQ), and N-(6-aminohexyl)-5-chloro-1-naphthalene sulfonamide (W-7) were obtained from Calbiochem.

Quantification of [3H]Arachidonic Acid Release from A-10 Smooth Muscle Cells

Rat smooth muscle A-10 cells were cultured in DMEM containing 20% fetal bovine serum at 37 °C as described previously (22). Briefly, A-10 cells (passages 5-10) were grown to confluence in DMEM containing 20% fetal bovine serum and incubated with 0.5 µCi of [3H]arachidonic acid for 16 h at 37 °C. After radiolabeling, the cells were repeatedly washed (× 2) in fresh DMEM containing 0.25% bovine serum albumin to remove unincorporated radiolabeled arachidonic acid. For studies employing BEL, cells were incubated with medium containing serum which had been previously heat-inactivated (56 °C for 1 h) to prevent enzymatic degradation of BEL by serum proteases during the preincubation period. Cells were incubated in this solution containing, in addition, either BEL (10 µM) or ethanol vehicle alone (0.1% final volume) for 15 min at 37 °C. The medium was removed, and the cells were incubated with fresh DMEM containing 0.25% bovine serum albumin and the indicated agonists or antagonists at 37 °C for the indicated times (typically 5 min). Fatty acids and phospholipids were extracted by a modified Bligh-Dyer procedure employing chloroform:methanol:distilled H2O (1:1:0.8; v/v) containing 2% acetic acid (final volume). The radiolabeled fatty acids were separated by TLC utilizing Silica Gel 60A plates with a mobile phase comprised of chloroform:methanol:acetic acid:distilled H2O (90:8:1:0.8, v/v), visualized by iodine staining of a fatty acid standard, scraped, and quantitated by scintillation spectrometry. Radiolabeled phospholipids and fatty acid from the cells were extracted by the Bligh-Dyer method, resolved by TLC employing a mobile phase of chloroform:methanol:ammonium hydroxide (65:25:5; v/v), and quantitated by scintillation spectrometry.

Measurement of Intracellular Calcium Concentration

Measurements of cytosolic calcium concentrations were conducted in Fura-2-loaded cells utilizing dual wavelength fluorescence recording at excitation wavelengths of 340 nm and 380 nm and an emission wavelength of 505 nm as described previously (22). The small deflections in the fluorescence ratio which precede the arrow in Figs. 1, 2, 3 reflect fluorescence changes due to mechanical agitation during addition of agonists.


Fig. 1. Arginine-vasopressin-mediated release of [3H]arachidonic acid from A-10 smooth muscle cells is attenuated by neomycin and is independent of alterations in intracellular calcium ion. a, A-10 muscle cells were prelabeled with 0.5 µCi of [3H]arachidonic acid for 16 h as described under "Experimental Procedures." Next, cells were pretreated with either BEL (10 µM) or vehicle alone for 15 min prior to exposure to AVP (1 µM) for 5 min in the absence or presence of neomycin (500 µM). The results are expressed as the percentage of [3H]arachidonic acid released from radiolabeled cellular phospholipids. b, A-10 muscle cells were prelabeled with 0.5 µCi of [3H]arachidonic acid for 16 h as described above. Next, the cells were pretreated with BEL (10 µM) or vehicle alone for 15 min and treated with BAPTA-AM (100 µM) for 30 min as indicated prior to exposure to AVP (1 µM) in medium containing calcium (2.5 mM) or EGTA (1 mM). The results are expressed as the percentage of [3H]arachidonic acid released from radiolabeled cellular phospholipids. c, A-10 smooth muscle cells were loaded with Fura 2-AM (5 µM) for 30 min and treated with BAPTA-AM (100 µM) for 30 min as indicated. The cells were placed in KRB buffer containing either calcium (2.5 mM) or EGTA (1 mM) and monitored by dual-wavelength fluorescence as described under "Experimental Procedures" during exposure to AVP (1 µM) (indicated by the arrow). The results are expressed as the 340/380 nm ratio, which is an index of intracellular calcium ion concentration and are representative of multiple independent single cell recordings.
[View Larger Version of this Image (15K GIF file)]



Fig. 2. Thapsigargin-induced intracellular calcium store depletion activates the iPLA2-mediated release of [3H]arachidonic acid from A-10 smooth muscle cells. a, A-10 smooth muscle cells were prelabeled with 0.5 µCi of [3H]arachidonic acid for 16 h as described under "Experimental Procedures." Next, the cells were pretreated with BEL (10 µM) or vehicle alone for 15 min and BAPTA-AM (100 µM) for 30 min as indicated prior to exposure to thapsigargin (5 µM) in medium containing either calcium (2.5 mM) or EGTA (1 mM). The results are expressed as the percentage of [3H]arachidonic acid released from radiolabeled cellular phospholipids. b, A-10 smooth muscle cells were loaded with Fura 2-AM (5 µM) for 30 min and treated with BAPTA-AM (100 µM) for 30 min as indicated. The cells were placed in KRB buffer containing either calcium (2.5 mM) or EGTA (1 mM) and monitored by dual-wavelength fluorescence as described under "Experimental Procedures" during exposure to thapsigargin (5 µM) (as indicated by the arrow). The results are expressed as the 340/380 nm ratio, which is an index of intracellular calcium ion concentration and are representative of multiple independent single cell recordings. c, A-10 smooth muscle cells were preincubated with 0.5 µCi of [3H]arachidonic acid for 16 h as described under "Experimental Procedures." The cells were exposed to AVP (1 µM) (diamond ), thapsigargin (5 µM) (square ), or vehicle alone (open circle ) for 0, 5, 10, and 15 min. The medium was removed, and the [3H]arachidonic acid was extracted and quantitated as described under "Experimental Procedures." The results are expressed as the percentage of [3H]arachidonic acid released from radiolabeled intracellular phospholipids.
[View Larger Version of this Image (15K GIF file)]



Fig. 3. A23187-induced depletion of intracellular calcium stores activates iPLA2-mediated release of arachidonic acid. a, A-10 smooth muscle cells were prelabeled with 0.5 µCi of [3H]arachidonic acid for 16 h as described under "Experimental Procedures." Cells were preincubated with either BEL (10 µM) or vehicle alone for 15 min and BAPTA-AM (100 µM) for 30 min as indicated prior to exposure to A23187 (10 µM) for 5 min in medium containing either calcium (2.5 mM) or EGTA (1 mM). The results are expressed as the percentage of [3H]arachidonic acid released from radiolabeled intracellular phospholipids. b, A-10 smooth muscle cells were loaded with Fura 2-AM (5 µM) for 30 min and treated with BAPTA-AM (100 µM) for 30 min as indicated. The cells were placed in KRB buffer containing either calcium (2.5 mM) or EGTA (1 mM) and monitored by dual-wavelength fluorescence as described under "Experimental Procedures" during exposure to A23187 (10 µM) (as indicated by the arrow).The results are expressed as the 340/380 nm ratio, which is an index of intracellular calcium ion concentration and are representative of multiple independent single cell recordings.
[View Larger Version of this Image (14K GIF file)]



RESULTS AND DISCUSSION

As previously demonstrated, treatment of prelabeled A-10 smooth muscle cells with AVP (1 µM) resulted in the robust release of [3H]arachidonic acid which was ablated by pretreatment with 10 µM BEL (BEL possesses a 1,000-fold selectivity for the inhibition of iPLA2 versus cPLA2 or sPLA2 (28) and does not attenuate AVP-induced activation of PLC in A-10 cells) (22) (Fig. 1a). Since A-10 smooth muscle cells contain receptors which are coupled to PLC and result in the IP3-mediated mobilization of intracellular calcium stores (26, 27), the effects of pharmacologic inhibition of intracellular calcium pool depletion on AVP-mediated activation of smooth muscle cell iPLA2 were investigated. Neomycin-mediated inhibition of PLC (29) decreased AVP-induced [3H]arachidonic acid release by 70% (Fig. 1a). Moreover, replacement of calcium in the incubation media with EGTA (1 mM) and BAPTA-AM (100 µM) did not attenuate AVP-induced [3H]arachidonic acid release, although alterations in [Ca2+]i were completely prevented (Figs. 1, b and c).

To determine whether intracellular calcium store depletion in the absence of receptor occupancy and IP3 production is a sufficient stimulus for iPLA2 activation, two independent approaches were taken. In the first approach, three structurally disparate inhibitors of sarco/endoplasmic reticular calciumATPases (SERCA) were employed to deplete intracellular calcium pools (30, 31). Thapsigargin-induced the robust release of [3H]arachidonic acid from A-10 cells which was inhibited by BEL. The magnitude of both the release of [3H]arachidonic acid by thapsigargin and its inhibition by BEL were identical when cells were stimulated in media containing 2.5 mM calcium, EGTA alone, or EGTA and BAPTA-AM (Fig. 2a). Treatment of smooth muscle cells with thapsigargin in the presence of medium containing EGTA resulted in a small increase in cytosolic calcium ion concentration which could be completely chelated by BAPTA-AM (Fig. 2b). Although BAPTA-AM completely prevented the modest thapsigargin-induced increments in cytosolic calcium concentration, no alterations in thapsigargin-induced release of [3H]arachidonic acid were manifest (Fig. 2a). Thus, thapsigargin-induced release of [3H]arachidonic acid is independent of alterations of cytosolic calcium ion concentration and is directly correlated with thapsigargin-induced depletion of intracellular calcium pools. Furthermore, the time course of thapsigargin-induced release of [3H]arachidonic acid was similar to that manifest by treatment of A-10 smooth muscle cells with AVP (Fig. 2c). Treatment of A-10 smooth muscle cells with two other structurally distinct SERCA inhibitors, cyclopiazonic acid (10 µM) (32) and BHQ (50 µM) (33), also resulted in similar increases in [3H]arachidonic acid release. These increases were entirely inhibited by BEL and the magnitude of the cyclopiazonic acid and BHQ-mediated [3H]arachidonic acid release was independent of alterations in [Ca2+]i which were ablated by BAPTA-AM treatment utilizing medium containing EGTA (data not shown). Collectively, these findings demonstrate that the depletion of intracellular calcium stores in A-10 smooth muscle cells by SERCA inhibitors results in the activation of smooth muscle cell iPLA2 independent of alterations in cytosolic calcium ion concentration.

In the second approach, the effects of intracellular calcium pool depletion on the activation of smooth muscle cell iPLA2 were investigated employing the calcium ionophore, A23187 (34). This compound mediates the passive transport of calcium ion across both plasma and intracellular membranes down existing [Ca2+] gradients, and thus can induce the depletion of calcium ion from intracellular sequestration sites. Treatment of A-10 smooth muscle cells with A23187(10 µM)for 5 min in the presence of 2.5 mM extracellular calcium resulted in the robust release of [3H]arachidonic acid which was entirely inhibited by BEL (Fig. 3a). Treatment of A-10 smooth muscle cells with A23187 (10 µM) in the presence of extracellular EGTA (5 mM) resulted in similar increases in[3H]arachidonic acid release (which was BEL-inhibitable) as those manifest in the presence of extracellular calcium ion (Fig. 3a). Moreover, A23187-induced release of [3H]arachidonic acid in the presence of external EGTA was not altered by BAPTA-AM, although BAPTA-AM completely prevented A23187-induced increases in cytosolic calcium ion (Fig. 3b).Collectively, these findings demonstrate that: 1) A23187 stimulation of A-10 smooth muscle cells mediates the release of [3H]arachidonic acid through iPLA2; 2) the A23187-induced release of [3H]arachidonic acid does not depend on either the entry of extracellular calcium ion or ionophore-induced increases in cytosolic calcium ion concentration; and 3) iPLA2 is exquisitely sensitive to alterations in intracellular calcium ion compartmentation.

Recently, calmodulin has been demonstrated to be physically associated with, and functionally coupled to, iPLA2 (24). To determine if the physical association of calmodulin with iPLA2 is causally related to the activation of iPLA2 by intracellular calcium pool depletion, we exploited the principle of pharmacologically directed radiolabeled phospholipid pool depletion.If Ca2+-store depletion activated latent iPLA2 activity through dissociation of the calmodulin iPLA2 complex, then prior exposure of cells to W-7 would deplete the [3H]arachidonic acid content of phospholipid pools which serve as substrates for iPLA2 and would result in decreased [3H]arachidonic acid release after subsequent exposure to thapsigargin. The results demonstrated that as the duration of pretreatment with W-7 increased, A-10 cells released progressively smaller amounts of [3H]arachidonic acid in response to subsequent thapsigargin treatment (Fig. 4). This suggests that activation of iPLA2, induced either by Ca2+-store depletion or by a calmodulin antagonist, results from the hydrolysis of a common pool of phospholipids.


Fig. 4. The calmodulin antagonist W-7 depletes [3H]arachidonic acid from the phospholipid pools which are the coupled to the activation of iPLA2 by depletion of intracellular calcium stores. A-10 smooth muscle cells were prelabeled with 0.5 µCi of [3H]arachidonic acid for 16 h as described under "Experimental Procedures." Next, the cells were incubated with W-7 (50 µM) or vehicle alone for 0, 5, 15, or 30 min. The medium was then removed, and the [3H]arachidonic acid content in the medium was quantified. W-7-induced [3H]arachidonic acid release was calculated as the [3H]arachidonic acid content of medium that had bathed W-7-exposed cells minus that of medium that had bathed vehicle-exposed cells. This value was expressed as a percentage of radiolabeled phospholipids (diamond ). Next, the cells that had been exposed to W-7 for selected intervals were then placed in fresh medium and stimulated with 5 µM thapsigargin for 5 min. The content of [3H]arachidonic acid in the medium was determined and expressed as a percentage of radiolabeled phospholipids (square ). This value is plotted as a function of the W-7 pretreatment interval that had preceded stimulation with thapsigargin.
[View Larger Version of this Image (17K GIF file)]


Collectively, the results of the present study demonstrate that what has been nominally termed a "calcium-independent" phospholipase A2 based on in vitro activity assays is actually profoundly modulated by alterations in calcium homeostasis in its natural context in vivo. Moreover, these studies provide a rationale and experimental proof which integrates the receptor-mediated activation of phospholipase C with the subsequent phospholipase A2-mediated release of arachidonic acid through the IP3-mediated depletion of internal calcium stores. A substantial body of literature has utilized the A23187-induced release of arachidonic acid as a bona fide indicator of the participation of calcium-dependent phospholipases A2 in arachidonic acid release (35-37). These results demonstrate that the interpretation of those experiments is more complex than previously anticipated.

The importance of alterations in calcium homeostasis and iPLA2 activation in the receptor-mediated release of arachidonic acid in many tissues is now well established (38-41). However, the mechanism through which calcium can modulate calcium-independent phospholipase A2 during signal transduction has previously represented a fundamental paradox. The present results provide a novel paradigm which links alterations in calcium homeostasis to the activation of iPLA2 activity through the calcium·calmodulin-mediated regulation of iPLA2 and the depletion of internal calcium stores. Thus, iPLA2 can function as a sensor of the filling state of internal calcium stores, and this sensor function is mediated by the calcium-dependent association of iPLA2 with calmodulin.

Finally, we point out that depletion of internal calcium pools has been causally linked to the activation of a plasma membrane calcium channel through an as yet unidentified second messenger (42-45). The demonstration of the coupling of iPLA2 activation with calcium pool depletion suggests that this second messenger is likely either a direct product of the iPLA2 reaction (e.g. arachidonic acid or lysolipids) or a downstream product whose synthesis is initiated by iPLA2 activation. It is our hope that the identification of the coupling of calcium pool depletion with the activation of iPLA2 will serve as a biochemical foundation to identify the second messenger(s), which facilitates the activation of store-operated plasma membrane calcium channels.


FOOTNOTES

*   This research was supported by National Institutes of Health Grant PO1 HL57278-01. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed: Division of Bioorganic Chemistry and Molecular Pharmacology, Washington University School of Medicine, 660 South Euclid, Box 8020, St. Louis, MO 63110. Tel.: 314-362-2690; Fax: 314-362-1402.
1    The abbreviations used are: cPLA2, cytosolic calcium-dependent phospholipase A2; iPLA2, calcium-independent phospholipase A2; sPLA2, secretory phospholipase A2; AVP, arginine-vasopressin; BAPTA-AM, 1,2-bis-(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester; BEL, (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one; IP3, inositol 1,4,5 trisphosphate; KRB, Krebs-Ringer bicarbonate buffer; PLC, phospholipase C; SERCA, sarco/endoplasmic reticular calcium ATPases; W-7, N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, HCl; BHQ, 2,5-di-(t-butyl)-1,4-hydroquinone; DMEM, Dulbecco's modified Eagle's medium.

REFERENCES

  1. Streb, H., Irvine, R. F., Berridge, M. J., and Shultz, I. (1983) Nature 306, 67-68 [Medline] [Order article via Infotrieve]
  2. Putney, J. W., Jr. (1987) Trends Pharmacol. Sci. 8, 481-486
  3. Berridge, M. J. (1990) J. Biol. Chem. 265, 9583-9586 [Free Full Text]
  4. Pietrobon, D., DiVirgilio, F., and Pozzan, T. (1990) Eur. J. Biochem. 193, 599-622 [Abstract]
  5. Berridge, M. J. (1993) Nature 361, 315-325 [CrossRef][Medline] [Order article via Infotrieve]
  6. Putney, J. W., Bird, G., and St, J. (1993) Endocr. Rev. 14, 610-631 [Medline] [Order article via Infotrieve]
  7. Phair, R. D. (1988) Cell Calcium 9, 275-284 [Medline] [Order article via Infotrieve]
  8. Rembold, C. M. (1992) Hypertension 20, 129-137 [Abstract]
  9. Himples, B., Missiaen, L., and Casteels, R. (1995) J. Vasc. Res. 32, 207-219 [Medline] [Order article via Infotrieve]
  10. Takemura, H., Hughes, A. R., Thastrup, O., and Putney, J. W., Jr. (1989) J. Biol. Chem. 264, 12266-12271 [Abstract/Free Full Text]
  11. Foskett, J. K., Roifman, C. M., and Wong, D. (1991) J. Biol. Chem. 266, 2778-2782 [Abstract/Free Full Text]
  12. Foskett, J. K., and Wong, D. (1992) Am. J. Physiol. 262, C656-C663 [Abstract/Free Full Text]
  13. Hoth, M., and Penner, R. (1992) Nature 355, 353-356 [CrossRef][Medline] [Order article via Infotrieve]
  14. Zhu, X., Jiang, M., Peyton, M., Boulay, G., Hurst, R., Stefani, E., and Birnbaumer, L. (1996) Cell 85, 661-667 [Medline] [Order article via Infotrieve]
  15. Roe, M. W., Lancaster, M. E., Mertz, R. J., Worley, J. F., III, and Dukes, I. D. (1993) J. Biol. Chem. 268, 9953-9956 [Abstract/Free Full Text]
  16. Tse, A., Tse, F. W., and Hille, B. (1994) J. Physiol. 477.3, 511-525
  17. Short, A. D., Bian, J., Ghosh, T. K., Waldron, R. T., Rybak, S. L., and Gill, D. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4986-4990 [Abstract]
  18. Ufret-Vincenty, C. A., Short, A. D., Alfonso, A., and Gill, D. L. (1995) J. Biol. Chem. 270, 26790-26793 [Abstract/Free Full Text]
  19. Waldron, R. T., Short, A. D., Meadows, J. J., Ghosh, T. K., and Gill, D. L. (1994) J. Biol. Chem. 269, 11927-11933 [Abstract/Free Full Text]
  20. Dennis, E. A. (1983) in The Enzymes (Boyer, P. D., ed), 3rd Ed., Vol. 16, pp. 307-353, Academic Press, New York
  21. Channon, J, Y, and Leslie, C. C. (1990) J. Biol. Chem. 265, 5409-5413 [Abstract/Free Full Text]
  22. Lehman, J. J., Brown, K. A., Ramanadham, S., Turk, J., and Gross, R. W. (1993) J. Biol. Chem. 268, 20713-20716 [Abstract/Free Full Text]
  23. Dennis, E. A. (1994) J. Biol. Chem. 269, 13057-13060 [Free Full Text]
  24. Wolf, M. J., and Gross, R. W. (1996) J. Biol. Chem. 271, 20989-20992 [Abstract/Free Full Text]
  25. Stassen, F. L., Heckman, G., Schmidt, D., Aiyar, N., Nambi, P., and Crooke, S. T. (1988) Mol. Pharmacol. 31, 259-266 [Abstract]
  26. Grillone, L. R., Clark, M. A., Godfrey, R. W., Stassen, F., and Crooke, S. T. (1988) J. Biol. Chem. 263, 2658-2663 [Abstract/Free Full Text]
  27. Bird, G., St, J., Oliver, K. G., Horstman, D. A., Obie, J., and Putney, J. W., Jr. (1992) Nature 352, 162-165 [CrossRef]
  28. Hazen, S. L., Zupan, L., Weiss, R. H., Getman, D. P., and Gross, R. W. (1991) J. Biol. Chem. 266, 7227-7232 [Abstract/Free Full Text]
  29. Carney, D. H., Scott, D. L., Gordon, E. A., and LaBelle, E. F. (1985) Cell 42, 479-488 [Medline] [Order article via Infotrieve]
  30. Thatrup, O., Cullen, P. J., Drobak, B. K., Hanley, M. R., and Dawson, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470 [Abstract]
  31. Lytton, J., Westlin, M., and Hanley, M. R. (1991) J. Biol. Chem. 266, 17067-17071 [Abstract/Free Full Text]
  32. Demaurex, N., Lew, D. P., and Krause, K.-H. (1992) J. Biol. Chem. 267, 2318-2324 [Abstract/Free Full Text]
  33. Mason, M. J., Garcia-Rodriguez, C., and Grinstein, S. (1991) J. Biol. Chem. 266, 20856-20862 [Abstract/Free Full Text]
  34. Pressman, B. C. (1976) Annu. Rev. Biochem. 45, 501-530 [CrossRef][Medline] [Order article via Infotrieve]
  35. Bauldry, S. A., Wykle, R. L., and Bass, D. A. (1988) J. Biol. Chem. 263, 16787-16795 [Abstract/Free Full Text]
  36. Alonso, F., Henson, P. M., and Leslie, C. C. (1986) Biochim. Biophys. Acta 878, 273-280 [Medline] [Order article via Infotrieve]
  37. Chilton, F. H., Ellis, J. M., Olson, S. C., and Wykle, R. L. (1984) J. Biol. Chem. 259, 12014-12019 [Abstract/Free Full Text]
  38. Hazen, S. L., Stuppy, R. J., and Gross, R. W. (1990) J. Biol. Chem. 265, 10622-10630 [Abstract/Free Full Text]
  39. Gross, R. W., Ramanadham, S., Kruszka, K. K., Han, X., and Turk, J. (1993) Biochemistry 32, 327-336 [Medline] [Order article via Infotrieve]
  40. Wolf, M. J., Izumi, Y., Zorumski, C. F., and Gross, R. W. (1995) FEBS Lett. 377, 358-362 [CrossRef][Medline] [Order article via Infotrieve]
  41. Portilla, D., and Dai, G. (1996) J. Biol. Chem. 271, 15451-15457 [Abstract/Free Full Text]
  42. Fasolato, C., Innocenti, B., and Pozzan, T. (1994) Trends Pharmacol. Sci. 15, 77-83 [CrossRef][Medline] [Order article via Infotrieve]
  43. Randriamapit, C., and Tsein, R. Y. (1993) Nature 364, 809-814 [CrossRef][Medline] [Order article via Infotrieve]
  44. Parekh, A. B., Terlau, H., and Stuhmer, W. (1993) Nature 364, 814-819 [CrossRef][Medline] [Order article via Infotrieve]
  45. Lee, H. C., Aarhus, R., Graeff, R., Gurnack, M. E., and Walseth, T. F. (1994) Nature 370, 307-309 [CrossRef][Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.